| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GRNA | Common Stock | Other | -29.8K | -100% | 0 | Jul 24, 2023 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | GRNA | Stock Option (Right to Buy) | Other | -105K | -100% | 0 | Jul 24, 2023 | Common Stock | 105K | $0.28 | Direct | F2, F3 |
Marta Ortega-Valle is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | This transaction reports securities contributed by the Reporting Person in connection with the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2023, by and among GreenLight Biosciences Holdings, PBC, SW ParentCo, Inc. ("Parent"), and SW MergerCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), to Merger Sub in exchange for shares of Series A-2 Preferred Stock, par value $0.001 per share, of Parent pursuant to a Contribution and Exchange Agreement, dated May 29, 2016 (the "Contribution and Exchange Agreement"), between Parent and the Reporting Person. The price used to calculate the value of each share of Series A-2 Preferred Stock for purposes of the exchange was $0.40 per share, as determined pursuant to the terms of the Contribution and Exchange Agreement. |
| F2 | On July 24, 2023, upon consummation of the merger transaction pursuant to the Merger Agreement (the "Effective Time"), each option to purchase shares of Common Stock, par value $0.0001 per share of the Issuer ("Common Stock"), granted under an Issuer equity plan with an exercise price per share less than $0.30 ("Merger Consideration") that was outstanding and unexercised (each an "In-the-Money Option") was cancelled and converted into the right to receive a cash payment equal to (A) the number of shares of Common Stock remaining subject to such In-the-Money Option immediately prior to the Effective Time multiplied by (B) the amount by which (x) the Merger Consideration exceeds (y) the per share exercise price for such In-the-Money Option. |
| F3 | 100% of the shares subject to this option are fully vested and exercisable. |